1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 2-2
&NA;,
Preview
|
PDF (819KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
Pharmacists in the futureevolve or die? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 3-4
Wayne Elwood,
Preview
|
PDF (1626KB)
|
|
摘要:
Over the next few years, over 40 000 pharmacists in the US will have to make themselves more valuable as the processes of automation and centralisation occur, otherwise they face the bleak prospect of being replaced by automated technology. The future of pharmacy in the changing healthcare environment may depend on the ability of the discipline to prove the value of pharmaceutical care in the provision of comprehensive healthcare. The future role of the profession was discussed at the 10th Annual Meeting of the National Managed Health Care Congress [Atlanta, US; April 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
Urgent need for effective, affordable pneumococcal vaccine |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 5-5
&NA;,
Preview
|
PDF (744KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
Methotrexate cost saving in unruptured ectopic pregnancy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 6-6
&NA;,
Preview
|
PDF (728KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
Risperidone cost-effective in refractory psychotic disorders? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 7-7
&NA;,
Preview
|
PDF (703KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 8-8
&NA;,
Preview
|
PDF (760KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
Trastuzumab targets metastatic breast cancer head on |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 9-10
Robert Carlsson,
Preview
|
PDF (1493KB)
|
|
摘要:
A revolutionary new anticancer agent, trastuzumab [‘Herceptin’; Genentech], which works against the most aggressive types of breast cancer was highlighted at the 34th Annual Meeting of the American Society of Clinical Oncology [Los Angeles, US; May 1998]. Trastuzumab is a humanised monoclonal antibody that was rationally designed to target the growth factor receptor HER2/neu.If it is approved by the US FDA it will be the first biological treatment for HER2-overexpressing metastatic breast cancer, an aggressive form of the disease that is associated with rapid disease progression and shortened survival. Final results from 2 major clinical trials showed that trastuzumab has activity when administered either as monotherapy or in combination with standard chemotherapy regimens.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 10-10
&NA;,
Preview
|
PDF (742KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 11-11
&NA;,
Preview
|
PDF (745KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1140,
1998,
Page 12-12
&NA;,
Preview
|
PDF (669KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|